SLC5A2 and hydrops fetalis: Beta-blockers, mineralocorticoid receptor antagonists (MRAs), neprilysin inhibitors, and sodium-glucose cotransporter-2 (SGLT2) inhibitors are medications designed to modulate the neurohormonal system and improve HF outcomes.